Laurus Labs has entered into a definitive agreement to acquire a 60% stake in Canada-based Galenvs Sciences, a company specializing in oligonucleotide technologies and precision magnetic nanoparticles. This strategic move aims to strengthen Laurus Labs’ capabilities in TIDES (Therapeutic Area) therapeutics and CDMO services, enhancing its position in the rapidly growing oligonucleotide market.
Laurus Labs Strengthens TIDES Capabilities with Galenvs Acquisition
Laurus Labs Ltd. announced today the signing of a definitive agreement to acquire a 60% majority ownership in Galenvs Sciences, a Montréal, Canada-based biotechnology company. Galenvs Sciences specializes in precision magnetic nanoparticles and DNA/RNA technologies, crucial for advanced diagnostics and therapeutics.
Strategic Rationale and Market Expansion
This strategic investment marks a significant step in Laurus Labs’ strategy to enhance its expertise in oligonucleotide development and manufacturing, thereby boosting its Contract Development and Manufacturing Organization (CDMO) offerings. The acquisition is expected to unlock greater efficiency and scalability in RNA and oligonucleotide manufacturing, enabling Laurus Labs to expand its presence in the fast-growing field of DNA/RNA-based precision therapeutics.
The integration of Galenvs Sciences’ specialized technology platforms with Laurus Labs’ research, development, and manufacturing capabilities is anticipated to create differentiated solutions for customers developing complex, next-generation therapeutics. The combined entity aims to build differentiated capabilities that can facilitate the development of advanced therapies more efficiently and at scale, ultimately bringing next-generation therapies to patients affordably.
Deal Terms and Investment
Under the terms of the definitive term sheet agreement signed on October 29, 2026, Laurus Labs Ltd. will acquire 60% of the equity share capital of Galenvs Sciences at a pre-money valuation of USD 3.50 million, subject to due diligence. Laurus Labs proposes to invest a total of USD 3.75 million, which includes a primary infusion of USD 2.75 million.
Complementary Strengths and Future Outlook
Dr. Satyanarayana Chava, Founder & Chief Executive Officer of Laurus Labs, stated that the investment in Galenvs Sciences is a pivotal step in the company’s strategic evolution. He highlighted Galenvs’ differentiated technology capabilities in oligonucleotides and precision magnetic nanoparticles as key value drivers for customers and a significant enhancement to Laurus’ TIDES capabilities.
The investment brings together complementary capabilities in the end-to-end Oligonucleotide segment, from early-stage process development, conjugation, and advanced purification technology to fill-finish. Laurus’ expertise in large-scale manufacturing, complex chemistry, fermentation, peptides, and sterile drug formulation will complement Galenvs’ strengths, creating a seamless offering for partners in the oligonucleotide space. The integration is expected to foster scientific talent development in Montréal and expand manufacturing infrastructure in India.
Dr. Jamal Daoud, Founder & Chief Executive Officer of Galenvs Sciences, expressed excitement about partnering with Laurus Labs at this important stage of Galenvs’ growth. He believes the combination will create a strong platform to serve customers from early-stage development through scale-up and manufacturing, with a shared vision to grow scientific capabilities globally.
Source: BSE
